Maryland House Bill HB1355

Maryland 2022 Regular Session

• Introduced: 2/11/22
• Refer: 2/11/22

Caption

Health Insurance - Prescription Insulin Drugs - Limits on Copayment and Coinsurance

Impact

If enacted, HB1355 is expected to significantly lower out-of-pocket expenses for individuals requiring insulin, potentially increasing adherence to prescribed treatments. The bill also instructs the Prescription Drug Affordability Board to conduct a cost review on insulin pricing practices and report on the implications for the state's healthcare system and patients' financial burdens. This measure aims to facilitate an analysis that could lead to further legislative actions designed to curtail rising drug prices and ensure equitable access to essential medications.

Summary

House Bill 1355 aims to address the affordability of prescription insulin drugs in Maryland by imposing limits on copayments and coinsurance. The bill mandates that insurers, nonprofit health service plans, and health maintenance organizations must cap the copayment for insulin drugs at a maximum of $30 for a 30-day supply. This initiative seeks to improve access to necessary medication for individuals suffering from diabetes, who often face exorbitant costs for insulin. The legislation reflects a growing concern over prescription drug pricing and its impact on public health.

Contention

The introduction of this bill has been met with both support and criticism. Proponents argue that capping copayments for insulin is vital for protecting patients from financial strain, particularly in the context of rising health care costs. However, opponents might raise concerns regarding the broader implications for insurers and the potential for unintended consequences in the insurance market. Detailed discussions are likely surrounding the balance between insurer profitability and patient affordability, as well as how such measures might influence overall healthcare costs in the state.